18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer

Journal of Nuclear Medicine

Volumn 50, Issue SUPPL. 1, 2009, Pages

  Krause, Bernd J ^a   Herrmann, Ken ^a   Wieder, Hinrich ^a   Zum Büschenfelde, Christian Meyer ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F FDG; Esophageal cancer; PET; PET CT; Therapy response

Indexed keywords

CD31 ANTIGEN; CD68 ANTIGEN; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE TRANSPORTER 1; HEXOKINASE; IRINOTECAN; KI 67 ANTIGEN; VASCULOTROPIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; ESOPHAGUS CANCER; ESOPHAGUS SCINTISCANNING; ESOPHAGUS SURGERY; HUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOISOTOPE DISTRIBUTION; REVIEW; TREATMENT RESPONSE; ESOPHAGUS TUMOR; IMAGE SUBTRACTION; METHODOLOGY; TREATMENT OUTCOME;

ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 66149092726     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.057232     Document Type: Review

References (45)

1. Parkin DM. International variation. Oncogene. 2004;23:6329-6340. (Pubitemid 39272833)
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-2252. (Pubitemid 37485141)
4. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26:2-8. (Pubitemid 29529530)
5. 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
6. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727-1734.
7. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234. (Pubitemid 46291702)
8. Cunningham D, Allum WH, Stenning SP, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
9. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167. (Pubitemid 27306287)
10. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-2174.
11. Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy-the second Scandinavian trial in esophageal cancer. World J Surg. 1992;16:1104-1109. (Pubitemid 23065529)
12. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73:1779-1784. (Pubitemid 24101950)
13. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41:391-393. (Pubitemid 24273251)
14. Boige V, Pignon J, Saint-Auberg B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial [abstract]. J Clin Oncol. 2007;25(suppl):18S.
15. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27:851-856.
16. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292. (Pubitemid 46622068)
17. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med. 2007;48(suppl):36S-44S.
18. Herrmann K, Krause BJ, Bundschuh R, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med. 2009. In press.
19. Beer AJ, Wieder HA, Lordick F, et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology. 2006;239:472-480.
20. Brücher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233:300-309. (Pubitemid 32187807)
21. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13:361-368. (Pubitemid 34704995)
22. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21:428-432.
23. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160. (Pubitemid 39303827)
24. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129:1232-1241. (Pubitemid 40804839)
25. 18F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43:1385-1391.
26. Port JL, Lee PC, Korst RJ, et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg. 2007;84:393-400. (Pubitemid 47079022)
27. Smithers BM, Couper GC, Thomas JM, et al. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Dis Esophagus. 2008;21:151-158.
28. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065. (Pubitemid 32565444)
29. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530. (Pubitemid 37151509)
30. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908. (Pubitemid 41103602)
31. Gillham CM, Lucey JA, Keogan M, et al. 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95:1174-1179. (Pubitemid 44658480)
32. 18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging. December 19, 2008 [Epub ahead of print].
33. Ribi K, Nitzsche E, Schuller J, et al. PET scanning and patient reported dysphagia before and after chemotherapy for prediction of pathological response after chemotherapy and chemoradiotherapy in patients with locally advanced esophageal cancer: a multicenter phase II trial of the Swiss. J Clin Oncology. 2007;25(suppl):219S.
34. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. (Pubitemid 46646244)
35. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. (Pubitemid 47308659)
36. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24:191-200.
37. Lordick F, Ruers T, Aust DE, et al; European Organisation of Research and Treatment of Cancer Gastrointestinal Group. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer. 2008;44:1807-1819.
38. 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400-404.
39. Choi JY, Jang KT, Shim YM, et al. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol. 2006;13:1054-1062. (Pubitemid 44337964)
40. Westerterp M, Sloof GW, Hoekstra OS, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol. 2008;134:227-236. (Pubitemid 350234068)
41. Weber WA, Czernin J, Phelps ME, Herschman HR. Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008;5:44-54.
42. Di Fabio F, Pinto C, Rojas Llimpe FL, et al. The predictive value of 18F-FDGPET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer. 2007;10:221-227. (Pubitemid 350308171)
43. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
44. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007;25:3712-3718. (Pubitemid 47372612)
45. Olaussen KA, Dunant A, Fouret P, et al; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991.